Improper Dose In Phase II Trials Can ‘Make Or Break’ Drug Program, FDA’s Stein Says

 
• By Brenda Sandburg
  
Drug dose
The FDA touts selecting the optimal dose early in clinical development. • Source: Alamy

More from Clinical Trials

More from Conferences